In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT

Journal of Nuclear Medicine

Volumn 51, Issue 1, 2010, Pages 31-36

  Seo, Youngho ^a   Aparici, Carina Mari ^a,b   Cooperberg, Matthew R ^a,b   Konety, Badrinath R ^a,b   Hawkins, Randall A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Capromab pendetide; Prostate cancer; Prostate specific membrane antigen (PSMA); Quantification; Quantitative SPECT; SPECT; SPECT CT; Tracer quantification

Indexed keywords

CAPROMAB PENDETIDE IN 111;

ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; IMAGE QUALITY; IN VIVO STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALGORITHMS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CALIBRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; NEOPLASM STAGING; PHANTOMS, IMAGING; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 75149155728     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.067108     Document Type: Article

References (25)

1. Jansen FP, Vanderheyden JL. The future of SPECT in a time of PET. Nucl Med Biol. 2007;34:733-735.
2. Flux G, Bardies M, Monsieurs M, Savolainen S, Strands SE, Lassmann M. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys. 2006;16:47-59.
3. Garcia EV. SPECT attenuation correction: an essential tool to realize nuclear cardiology's manifest destiny. J Nucl Cardiol. 2007;14:16-24.
4. Manyak MJ. Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther. 2008;8:175-181.
5. 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:834-840.
6. Fair WR, Israeli RS, Heston WD. Prostate-specific membrane antigen. Prostate. 1997;32:140-148.
7. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-640.
8. Seo Y, Mari C, Hasegawa BH. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med. 2008;38:177-198.
9. Seo Y, Wong KH, Hasegawa BH. Calculation and validation of the use of effective attenuation correction for attenuation correction in In-111 SPECT. Med Phys. 2005;32:3628-3635.
10. Seo Y, Wong KH, Sun M, Franc BL, Hawkins RA, Hasegawa BH. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. J Nucl Med. 2005;46:868-877.
11. Song X, Segars WP, Du Y, Tsui BM, Frey EC. Fast modelling of the collimator-detector response in Monte Carlo simulation of SPECT imaging using the angular response function. Phys Med Biol. 2005;50:1791-1804.
12. Vandervoort E, Celler A, Harrop R. Implementation of an iterative scatter correction, the influence of attenuation map quality and their effect on absolute quantitation in SPECT. Phys Med Biol. 2007;52:1527-1545.
13. Celler A, Dixon KL, Chang Z, Blinder S, Powe J, Harrop R. Problems created in attenuation-corrected SPECT images by artifacts in attenuation maps: a simulation study. J Nucl Med. 2005;46:335-343.
14. Tsui BM, Gullberg GT, Edgerton ER, et al. Correction of nonuniform attenuation in cardiac SPECT imaging. J Nucl Med. 1989;30:497-507.
15. Teo BK, Seo Y, Bacharach SL, et al. Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med. 2007;48:802-810.
16. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945.
17. Seo Y. Prostate-bladder phantom for radionuclide imaging research. In: Nuclear Science Symposium Conference Record. Piscataway, NJ: IEEE; 2008:4820-4822.
18. Huang SC. Anatomy of SUV: standardized uptake value. Nucl Med Biol. 2000;27:643-646.
19. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804-814.
20. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992;23:273-279.
21. Seo Y, Franc BL, Hawkins RA, Wong KH, Hasegawa BH. Progress in SPECT/CT imaging of prostate cancer. Technol Cancer Res Treat. 2006;5:329-336.
22. Swanson MG, Vigneron DB, Tran TK, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. Cancer Invest. 2001;19:510-523.
23. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932-6940.
24. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol. 2006;175:1337-1340.
25. Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol. 2006;175:547-551.